Document is current
Any future updates will be listed below
-
Authors
Kokolus, Kathleen M https://orcid.org/0000-0002-9088-5409
Huck, Connor J
Connors, Eoghan L
Cortes-Gomez, Eduardo
Wang, Jianmin
Obermajer, Natasa https://orcid.org/0000-0002-0838-7508
Basse, Per H
Kalinski, Pawel PhD https://orcid.org/0000-0001-7025-3562
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02432378 at ClinicalTrials.govnct03599453 at ClinicalTrials.govDocuments that mention this clinical trial
Advanced Clinical Trials of Dendritic Cell Vaccines in Ovarian Cancer
https://doi.org/10.1136/jim-2020-001355
Synergy between TLR3-ligand and IFN-α in the transient sensitization of “Cold” tumors to PD-1 blockade and the induction of systemic immunity
https://doi.org/10.1136/jitc-2025-012307
nct04081389 at ClinicalTrials.govDocuments that mention this clinical trial
Synergy between TLR3-ligand and IFN-α in the transient sensitization of “Cold” tumors to PD-1 blockade and the induction of systemic immunity
https://doi.org/10.1136/jitc-2025-012307
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
https://doi.org/10.1136/jitc-2024-010058
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx
https://doi.org/10.1136/jitc-2023-007381
nct03599453 at ClinicalTrials.govDocuments that mention this clinical trial
Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy
https://doi.org/10.1136/jitc-2024-010960
Synergy between TLR3-ligand and IFN-α in the transient sensitization of “Cold” tumors to PD-1 blockade and the induction of systemic immunity
https://doi.org/10.1136/jitc-2025-012307
547 Safety and efficacy of de-escalated neoadjuvant chemoimmunotherapy of triple negative breast cancer (TNBC) using chemokine-modulating regimen (rintatolimod, IFN-α2b, celecoxib)
https://doi.org/10.1136/jitc-2022-sitc2022.0547
321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer
https://doi.org/10.1136/jitc-2020-sitc2020.0321
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
https://doi.org/10.1136/jitc-2024-010058
nct05756166 at ClinicalTrials.govDocuments that mention this clinical trial
Synergy between TLR3-ligand and IFN-α in the transient sensitization of “Cold” tumors to PD-1 blockade and the induction of systemic immunity
https://doi.org/10.1136/jitc-2025-012307
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
https://doi.org/10.1136/jitc-2024-010058
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx
https://doi.org/10.1136/jitc-2023-007381
nct03599453 at ClinicalTrials.govDocuments that mention this clinical trial
Synergy between TLR3-ligand and IFN-α in the transient sensitization of “Cold” tumors to PD-1 blockade and the induction of systemic immunity
https://doi.org/10.1136/jitc-2025-012307
nct05756166 at ClinicalTrials.govDocuments that mention this clinical trial
Synergy between TLR3-ligand and IFN-α in the transient sensitization of “Cold” tumors to PD-1 blockade and the induction of systemic immunity
https://doi.org/10.1136/jitc-2025-012307
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
https://doi.org/10.1136/jitc-2024-010058
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx
https://doi.org/10.1136/jitc-2023-007381
Documents that mention this clinical trial
Synergy between TLR3-ligand and IFN-α in the transient sensitization of “Cold” tumors to PD-1 blockade and the induction of systemic immunity
https://doi.org/10.1136/jitc-2025-012307
-
Funding
Funding for this research was provided by:
NIH/NCATS (UL1TR001412)
Jacobs Family Foundation (N/A)
NIH/NCI (P01CA234212)
Rustum Family Foundation (N/A)
Roswell Park Alliance Foundation (N/A)
Roswell Park Comprehensive Cancer Center (N/A)
- License Information
